High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. D-chiro-inositol effectively attenuates cholestasis in bile duct ligated rats by improving bile acid secretion and attenuating oxidative stress.Acta pharmacologica Sinica · 2018
   Article
2. Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis.The Cochrane database of systematic reviews · 2017
   Review
3. Management of primary sclerosing cholangitis.World journal of hepatology · 2011
   Article
4. Primary sclerosing cholangitis: what is the role of ursodeoxycholic acid in therapy for PSC?Nature reviews. Gastroenterology & hepatology · 2010
   Article

Corrections and comments

• Comment on
  High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.2009

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as